Meta-Analysis of the Treatment of Posttraumatic Stress Disorder in Adults With Comorbid Severe Mental Illness

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article.

Overview

For patients who have PTSD and also have a severe mental illness, can psychotherapies for PTSD still be effective? If so, what component might offer greater efficacy?


Read the whole article at psychiatrist.com here: 
Meta-Analysis of the Treatment of Posttraumatic Stress Disorder in Adults With Comorbid Severe Mental Illness

© Copyright 2021 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Use evidence-based psychotherapies for PTSD whether or not patients have comorbid bipolar disorder or schizophrenia

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
05/25/2021
Activity expires: 
06/30/2023
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Use evidence-based psychotherapies for PTSD whether or not patients have comorbid bipolar disorder or schizophrenia

Statement of Need and Purpose

Evidence-based treatments for PTSD are underused in patients with comorbid SMI, due in large part to clinicians’ misperceptions of their efficacy and appropriateness in these patients. Increasing awareness of the relative efficacy of various treatments for PTSD such as prolonged exposure, eye movement desensitization and reprocessing, and cognitive processing therapy may lead to greater use of these therapies in people with SMI and thus to improved patient care.

Release, Expiration, and Review Dates

This educational activity was published in May 2021 and is eligible for AMA PRA Category 1 Credit™ through June 30, 2023. The latest review of this material was May 2021.

Disclosure of Off-Label Usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.

Author contributions

All authors contributed to the development of the submitted manuscript. Drs Grubaugh and Brown contributed to the conceptualization, research of background/studies for inclusion, methodology, analysis, and write-up. Dr Wojtalik contributed to the research of background/studies for inclusion, methodology, analysis, and write-up. Dr Myers contributed to the research of background/studies for inclusion and write-up. Dr Eack contributed to the methodology, analysis, and write-up.

Funding/Support

No direct funding/financial support was received for this work.


[COPY ANY REMAINING FRONT/BACKMATTER FROM ARTICLE]

Faculty Affiliation

Anouk L. Grubaugh, PhD*
Ralph H. Johnson Veterans Affairs Medical Center and Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina

Wilson J. Brown, PhD
School of Humanities and Social Sciences, Pennsylvania State University, The Behrend College, Erie, Pennsylvania

Jessica A. Wojtalik, PhD
Jack, Joseph, & Morton Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, Ohio

Ursula S. Myers, PhD
Ralph H. Johnson Veterans Affairs Medical Center and Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina

Shaun M. Eack, PhD
School of Social Work, University of Pittsburgh, and Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

*Corresponding author: Anouk L. Grubaugh, PhD, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, PO Box 250861, Charleston, SC 29425 (grubaugh@musc.edu).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

Drs Grubaugh, Brown, Wojtalik, Myers, and Eack have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.